A PROSPECTIVE INTERVENTIONAL COMPARATIVE LONG-TERM STUDY ON THE EFFICACY OF CANAGLIFLOZIN AND DAPAGLIFLOZIN IN A TERTIARY CARE HOSPITAL FOR A SPAN OF 1 YEAR

DHANUSH BELLAPU; RONALD DARWIN

doi:10.22159/ajpcr.2025v18i7.54767

Authors

DHANUSH BELLAPU Department of Pharmacy Practice, School of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India https://orcid.org/0009-0004-6805-7545
RONALD DARWIN Department of Pharmacology, School of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2025v18i7.54767

Keywords:

Sodium-glucose cotransporter-2 inhibitors, Canagliflozin, Dapagliflozin, Effectiveness

Abstract

Objectives: This study mainly focuses on the comparison between the efficacy of canagliflozin and dapagliflozin by observing the prolonged effects, quality of life of patients, and comparing them with patients prescribed antihyperglycemic agents other than sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Methods: This prospective interventional comparative study was conducted among 3452 patients admitted to the general medicine and endocrine department, Anu Group of Hospitals, Vijayawada, for 1 year, by eluding the patient’s fasting blood sugar, postprandial blood sugar, renal function test, Hemoglobin A1c, blood pressure, and the finding severity score of adverse drug reaction (ADR) using the Naranjo scale during the study.

Results: The most common ADRs after utilizing canagliflozin was hypotension and dapagliflozin wes dehydration. The Chi-square test for patients with ADR’s after using canagliflozin versus dapagliflozin used to treat type 2 diabetes. 9.12529 is the calculated Chi-square value at 5° of freedom and 5% level of significance (p<0.1042 – not significant). This shows that there was a slight difference but similar effects using canagliflozin versus dapagliflozin. The positive effect after treatment was weight reduction, which was greater in canagliflozin. Negative effects were hypotension, dehydration, infections, polyuria, and ketoacidosis, which were greater in canagliflozin.

Conclusion: We concluded that females were affected by urinary tract infection and vaginal infection. Efficacy was similar in control, canagliflozin, and dapagliflozin, but it may be a cost-related burden.

Downloads

Download data is not yet available.

References

Pfister M, Whaley JM, Zhang L, List JF. Inhibition of SGLT2: A novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther. 2011;89(4):621-5. doi: 10.1038/clpt.2011.16, PMID 21346749

Chinnakadoori SR, Reddy SM, Bodapati A, Madhuri Kallam SD, Dharmamoorthy G, Gupta JK, et al. Biological exploration of ((substituted-phenyl-1H-pyrazol-4-yl) methylene) aniline derivatives as potential DPP-IV inhibitors: ADMET screening, molecular docking, and dynamics simulations. Chem Methodol. 2025;9(1):52-80.

Aminu KS, Uzairu A, Abechi SE, Shallangwa GA, Umar AB. A search for novel antidiabetic agents using ligand-based drug design and molecular docking studies employing human intestinal maltase-glucoamylase as model enzyme. Adv J Chem Sect A. 2023;6(2):155-71.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14;385(16):1451-61. doi: 10.1056/NEJMoa2107038, PMID 34449189

Nakka S, Gadthey S, Seema A, Marapakala K. Green assessment of stability indicating RP-HPLC method for simultaneous estimation of metformin, empagliflozin, and linagliptin in bulk and fixed dosage forms using AGREE and GAPI tools. Asian J Green Chem. 2024;8(5):623-41.

Muralidharan V, Sachdeo RA, Singh LP, Haque MA, Panigrahy UP, Mishra AK, et al. Molecular docking and dynamic simulation with ADMET exploration of natural products atlas compound library to search for potential alpha amylase inhibitors for the T2DM treatment. Chem Methodol. 2025;9(2):81-102.

Yadav NK, Mazumder R, Rani A, Kumar A. Current perspectives on using nanoparticles for diabetes management. Int J Appl Pharm. 2024;16(5):38-45. doi: 10.22159/ijap.2024v16i5.51084

Behera BP. Sen RK. A study on the prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus in a tertiary centre in a tribal population of eastern India. Int J Pharm Pharm Sci. 2023;15(6):29-34.

Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020 Apr 14;323(14):1353-68. doi: 10.1001/ jama.2020.1906, PMID 32219386

ADA. Statistics about Diabetes: American Diabetes Association®. American Diabetes Association Diabetes State; 2017. Available from: https://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav

Patel J. Diabetes, a Global Epidemic. John Heinrichs Sch Creat Act Day; 2023. Available from: https://scholars.fhsu.edu/sacad/vol2023/ iss2023/103.

Narwat A, Goyal A, Bhati R. A systematic review on adherence to oral antidiabetic drugs in patients with type 2 diabetes mellitus. Int J Curr Pharm Res. 2024;16(6):16-8.

Shekhar R. A cross-sectional study of thyroid disorder in patients with type 2 diabetes mellitus in a tertiary care hospital. Asian J Pharm Clin Res. 2022;15(8):46-50.

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Ann Intern Med. 2019 Jun 4;170(11):764-9. doi: 10.7326/M19-0085, PMID 31060053

Samiya SS, Saha S, Jakhmola V, Gairola N, Singh M. Molecular docking, synthesis, antiproliferative activity against MCF-7, and in-vitro alpha amylase activities of newer generation pyrimidino hydroxamic acid derivatives. Int J Drug Deliv Technol. 2024;14(2):649-59. doi: 10.25258/ijddt.14.2.06

Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8, PMID 27009625

Alifah K, Wiyono N, Arifianto H. Bibliometric analysis and content review of current perspective on heart failure with mildly reduced ejection fraction therapy. J Med Chem Sci. 2024;7:2003-15.

Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57. doi: 10.1056/ NEJMoa1611925, PMID 28605608

Guthrie R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Postgrad Med. 2018;130(2):149-53. doi: 10.1080/00325481.2018.1423852, PMID 29297732

Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: A review of current evidence. Int J Heart Fail. 2023;5(2):82-90. doi: 10.36628/ijhf.2022.0030, PMID 37180562

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384-95. doi: 10.1161/CIRCULATIONAHA.118.037778, PMID 30586757

Mahaffey KW, Neal B, Perkovic V, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2018;137(4):323-34. doi: 10.1161/CIRCULATIONAHA.117.032038, PMID 29133604

Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, et al. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017;18(5):1083. doi: 10.3390/ijms18051083, PMID 28524098

Patil SM, Manu G, Ramya CM, Rajashekhara S, Desai SM, Parameswaran S, et al. Exploring jackfruit flour polyphenols as promising sglt-2 inhibitors for hyperglycemia management. Int J Appl Pharm. 2025;17(1):199-208. doi: 10.22159/ijap.2025v17i1.52573

Nelinson DS, Sosa JM, Chilton RJ. Sglt2 inhibitors: A narrative review of efficacy and safety. J Osteopath Med. 2021;121(2):229-39. doi: 10.1515/jom-2020-0153, PMID 33567084

Kani R, Miyamoto Y, Saito T, Watanabe A, Matsubara K, Ejiri K, et al. Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: A systematic review and meta-analysis. Int J Cardiol. 2025 May;426:133079. doi: 10.1016/j. ijcard.2025.133079, PMID 39983878

Liu JJ, Lee TW, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199-204. doi: 10.2337/db12-0052, PMID 22923645

Deshmukh AB, Patel MC, Mishra B. SGLT2 inhibition: A novel prospective strategy in treatment of diabetes mellitus. Ren Fail. 2013;35(4):566-72. doi: 10.3109/0886022X.2013.766560, PMID 23438184

Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014, PMID 24735709

Jabbour SA. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Ther Res. 2016;37(4):392-3.

Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22. doi: 10.2337/ dc11-0606, PMID 21816980

Inagaki N, Harashima SI, Kaku K, Kondo K, Maruyama N, Otsuka M, et al. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2018 Apr 5;20(4):812-20. doi: 10.1111/dom.13152, PMID 29110384

Rochmah N, Perwitasari RK, Hisbiyah Y, Rosyidah LN, Ni’mah NL, Kusumastuti NP, et al. Factors affecting insulin-like growth factor-1 in type 1 diabetes mellitus in children. J Med Pharm Chem Res. 2025;7(1):120-8.